LOVIT randomized trial of intravenous vitamin C in ICU patients with sepsis; important later evidence that tempered enthusiasm for routine vitamin C use.
Paul Marik HAT Sepsis Protocol
Hydrocortisone, ascorbic acid/vitamin C, and thiamine approach associated with Paul E. Marik for severe sepsis and septic shock. Its cancer connection is supportive critical-care use: cancer patients can develop neutropenic sepsis or septic shock during treatment, but HAT is not a cancer treatment. Connection to Cancer The Paul Marik HAT Sepsis Protocol combines hydrocortisone, ascorbic acid/vitamin C.
International sepsis guideline document; includes current critical-care guidance and vitamin C recommendation context.
VICTAS randomized clinical trial evaluating vitamin C, thiamine, and hydrocortisone for sepsis-associated cardiovascular or respiratory dysfunction.
ACTS randomized clinical trial; combination therapy did not significantly reduce organ injury score change within 72 hours after enrollment.
VITAMINS randomized clinical trial; combination therapy did not significantly improve time alive and free of vasopressor support compared with hydrocortisone alone.
Original before-after study reporting improved outcomes with hydrocortisone, vitamin C, and thiamine in severe sepsis and septic shock.
Review of biologic rationale and evolving clinical evidence for ascorbic acid, corticosteroids, and thiamine in sepsis.
Cancer-focused sepsis literature context; included to explain why a sepsis protocol belongs in an oncology support database.
Patient-facing explanation of neutropenic sepsis as an emergency complication during cancer treatment.
Systematic review and network meta-analysis on HAT components in sepsis and septic shock.